Is the Options Market Predicting a Spike in Arbutus Biopharma (ABUS) Stock?Zacks Investment Research • 08/23/21
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/05/21
Arbutus Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/05/21
Arbutus to Report Second Quarter 2021 Financial Results and Provide Corporate UpdateGlobeNewsWire • 07/29/21
Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi AgentGlobeNewsWire • 07/07/21
Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus InfectionGlobeNewsWire • 07/06/21
Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term InvestmentSeeking Alpha • 06/29/21
Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus InfectionGlobeNewsWire • 06/29/21
Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL International Liver Congress™ 2021 - All Selected for Best of ILC™GlobeNewsWire • 06/26/21
Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in JuneGlobeNewsWire • 06/02/21
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/05/21
Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/05/21
Arbutus to Report First Quarter 2021 Financial Results and Provide Corporate UpdateGlobeNewsWire • 04/28/21
Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License AgreementGlobeNewsWire • 04/01/21
Arbutus Receives Regulatory Approval to Initiate a Phase 1a/1b Clinical Trial with AB-836, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B InfectionGlobeNewsWire • 03/16/21